We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SCOTTSDALE, Ariz. — A novel therapeutic approach ...

Please provide your email address to receive an email when new articles are posted on . Our cover story this month is on the next wave of immune-based therapies for patients with immune-mediated ...

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations. Farmakidis explains how ...

Clinicians in Europe may soon gain access to a first-in-class neonatal Fc receptor (FcRn) inhibitor for generalized myasthenia gravis (gMG). Imaavy (nipocalimab; Janssen-Cilag International) received ...

Autoimmune drug development increasingly recognizes that the Fc-FcR axis is more than an effector mechanism; it is a controllable immunological node that bridges humoral and cellular responses. This ...

In the ever changing biotherapeutics landscape, antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) success hinges on more than simply antigen recognition. While the Fab region controls ...